Summaries & Associations of Study Results
TR-504 o-Nitrotoluene
Target Organs and Levels of Evidence
NTP Technical Report Number 504
Produced from Chemtrack Database 09/19/01
| CHEMICAL/ CAS NUMBER | PEER REVIEW DATE | PRIMARY USES | ROUTE/EXPOSURE LEVELS | STUDY LABORATORY |
|---|---|---|---|---|
| O-NITROTOLUENE 88-72-2 |
05/03/01 | INTERMEDIATE FOR TOLUIDINES, ORGANIC SYNTHESIS OF PESTICIDES, PHARMACEUTICALS, MFR OF DYES, RUBBER CHEMICALS | Dosed-Feed MR: 0, 625, 1250, 2000, OR 5000 PPM FR: 0, 625, 1250, OR 2000 PPM M: 0, 1250, 2500, OR 5000 PPM; 60/SEX/DOSE | Southern Research Institute |
| LEVELS OF EVIDENCE OF CARCINOGENICITY--ORGAN/TISSUE (NEOPLASM): | ||||
| MR: CLEAR EVIDENCE | MESOTHELIUM: MALIGNANT MESOTHELIOMA 2/60 20/60 29/60 44/60 44/60 54/60 | |||
| SKIN (SUBCUTANEOUS): LIPOMA 0/60 4/60 13/60 13/60 10/60 12/60 FIBROMA 5/60 46/60 52/60 59/60 45/60 52/60 FIBROSARCOMA 0/60 7/60 17/60 20/60 8/60 12/60 COMBINED 5/60 47/60 55/60 59/60 47/60 53/60 | ||||
| MAMMARY GLAND: FIBROADENOMA 0/60 7/60 10/60 2/60 13/60 20/60 | ||||
| LIVER: ADENOMA 2/60 3/60 3/60 7/60 3/60 4/60 ADENOMA OR CARCINOMA 3/60 3/60 3/60 8/60 3/60 6/60 CHOLANGIOCARCINOMA 0/60 0/60 0/60 0/60 0/60 3/60 HEPATOCHOLANGIOCARCINOMA 0/60 1/60 0/60 1/60 0/60 0/60 | ||||
| LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA 1/60 5/60 1/60 2/60 3/60 8/60 OR ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA 2/60 5/60 1/60 2/60 3/60 11/60 | ||||
| OTHER :CONSIDERATIONS: | DECREASED INCIDENCES: (MONONUCLEAR CELL LEUKEMIA) 30/60 21/60 3/60 3/60 13/60 1/60 | |||
| DECREASED INCIDENCES: (TESTIS: INTERSTITIAL CELL ADENOMA) 55/60 53/60 51/60 46/60 50/60 27/50 | ||||
| NON-NEOPLASTIC LESIONS: | LIVER: EOSINOPHILIC FOCUS; MIXED CELL FOCUS; CLEAR CELL FOCUS; MIXED CELL CELLULAR INFILTRATION | |||
| BONE MARROW: HYPERPLASIA | ||||
| SPLEEN: HEMATOPOIETIC CELL PROLIFERATION | ||||
| LUNG: ALVEOLAR EPITHELIAL HYPERPLASIA | ||||
| FR: CLEAR EVIDENCE | SKIN (SUBCUTANEOUS): FIBROMA 3/59 3/60 18/60 19/60 FIBROMA OR FIBROSARCOMA 3/60 3/60 21/60 22/60 | |||
| MAMMARY GLAND: FIBROADENOMA 23/60 47/60 52/60 56/60 | ||||
| OTHER :CONSIDERATIONS: | DECREASED INCIDENCES: (MONONUCLEAR CELL LEUKEMIA) 21/60 6/60 4/60 5/60 | |||
| MAY HAVE BEEN RELATED: | LIVER: ADENOMA 1/60 0/59 1/60 6/60 | |||
| NON-NEOPLASTIC LESIONS: | MAMMARY GLAND: HYPERPLASIA | |||
| LIVER: EOSINOPHILIC FOCUS; MIXED CELL FOCUS, CLEAR CELL FOCUS; BASOPHILIC FOCUS | ||||
| BONE MARROW: HYPERPLASIA | ||||
| SPLEEN: HEMATOPOIETIC CELL PROLIFERATION | ||||
| LUNG: ALVEOLAR EPITHELIAL HYPERPLASIA | ||||
| LYMPH NODE (MANDIBULAR): LYMPHOID HYPERPLASIA | ||||
| MM: CLEAR EVIDENCE | CIRCULATORY SYSTEM: HEMANGIOSARCOMA 4/60 17/60 55/60 60/60 | |||
| INTESTINES (CECUM): CARCINOMA 0/60 12/60 9/60 0/60 | ||||
| NON-NEOPLASTIC LESIONS: | LIVER: EOSINOPHILIC FOCUS; BASOPHILIC FOCUS, HEPATOCYTE NECROSIS; FOCAL HEPATOCYTE SYNCYTIAL ALTERATION | |||
| KIDNEY: TUBULAR PIGMENTATION | ||||
| NASAL CAVITY: OLFACTORY EPITHELIUM DEGENERATION | ||||
| FM: CLEAR EVIDENCE | CIRCULATORY SYSTEM: HEMANGIOSARCOMA 0/60 2/60 3/60 50/60 | |||
| INTESTINES (CECUM): CARCINOMA 0/60 1/60 4/60 3/60 | ||||
| LIVER: ADENOMA 7/60 5/59 19/59 29/60 CARCINOMA 2/60 4/59 6/59 16/60 COMBINED 9/60 9/59 24/59 39/60 | ||||
| NON-NEOPLASTIC LESIONS: | LIVER: EOSINOPHILIC FOCUS; BASOPHILIC FOCUS; HEPATOCYTE NECROSIS; FOCAL HEPATOCYTE NECROSIS; FOCAL HEPATOCYTE CYTOPLASMIC VACUOLIZATION | |||
| KIDNEY: TUBULAR PIGMENTATION | ||||
| NASAL CAVITY: OLFACTORY EPITHELIUM DEGENERATION | ||||
Web page last updated on February 10, 2006
